Corcept Therapeutics (CORT) Common Equity (2010 - 2026)

Corcept Therapeutics has reported Common Equity for 17 years, with the latest figure at $705.8 million in Q2 2026.

• Quarterly Common Equity rose 11.01% year-over-year to $705.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $705.8 million (up 11.01% YoY) and the FY2025 annual result came in at $647.8 million, down 4.68% from the prior year.
• Common Equity advanced to $705.8 million in Q2 2026 per CORT's latest filing, from $638.0 million in the prior quarter.
• Over five years, Common Equity peaked at $705.8 million in Q2 2026 and troughed at $407.8 million in Q1 2022.
• A 5-year average of $563.9 million and a median of $572.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity slipped 20.16% in 2022, then soared 41.42% in 2024.
• Over 5 years, Common Equity stood at $501.8 million in 2022, then advanced by 0.97% to $506.7 million in 2023, then jumped by 34.12% to $679.6 million in 2024, then fell by 4.68% to $647.8 million in 2025, then rose by 8.95% to $705.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $705.8 million, $638.0 million, and $647.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.